Aktienanalyse zu Moleculin Biotech Inc (MBRX)MBRXMoleculin Biotech Inc

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Moleculin Biotech Inc (MBRX) is a good buy right now due to its recent positive clinical trial results showing complete remission rates of 43% for Annamycin, significantly outperforming standard chemotherapy's 12%. The stock has seen a 62.48% increase over the last 20 days, indicating strong momentum. However, the main risk is the company's negative cash flow, with a net income loss of $14.61 million in Q1 2026, which raises concerns about its financial sustainability without further funding.

1 analysts cover MBRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.